• 1
    National Cancer Institute of Canada. Canadian cancer statistics 2005. Toronto, Ontario: National Cancer Institute of Canada, 2005.
  • 2
    Parmiani G, Mortarini R, Castelli C. Immunological relationship between melanoma and host. In: CascinelliN, SantinamiM, VeronesiU, editors. Cutaneous melanoma biology and management. Milan: Masson; 1990: 139151.
  • 3
    Kang S, Serri F, Sober AJ. Regressing melanoma and depigmentation. In: CascinelliN, SantinamiM, VeronesiU, editors. Cutaneous melanoma biology and management. Milan: Masson; 1990: 159166.
  • 4
    Chakraborty NG, Okino T, Stabach P, et al. Adoptive transfer of activated human autologous macrophages results in regression of transplanted human melanoma cells in SCID mice. In Vivo. 1991; 5: 609614.
  • 5
    Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a Phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1991; 9: 729735.
  • 6
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14: 717.
  • 7
    Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190. J Clin Oncol. 2000; 18: 24442458.
  • 8
    Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected Stage IIB–III melanoma: results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol. 2001; 19: 23702380.
  • 9
    Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995; 13: 27762783.
  • 10
    Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol. 2002; 20: 18181825.
  • 11
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 17788.
  • 12
    Meyskens FL Jr., Kopecky KJ, Taylor CW, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst. 1995; 87: 17101713.
  • 13
    Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised Phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer. 2004; 40: 390402.
  • 14
    McKenna RM, Oberg KE. Antibodies to interferon-alpha in treated cancer patients: incidence and significance. J Interferon Cytokine Res. 1997; 17: 141143.
  • 15
    Mitchell MS, Abrams J, Kashani-Sabet M, Thompson J, for the Ad Hoc Melanoma Study Group. Interim analysis of a Phase III stratified randomized trial of Melacine + low-dose interferon-a versus high-dose interferon-a for resected Stage III melanoma [abstract 2851]. Proc Am Soc Clin Oncol. 2004; 22: 709.
  • 16
    Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996; 14: 26662673.
  • 17
    Kirkwood J, Manola J, Ibrahim J, Sondak VK, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004; 10: 16701677.
  • 18
    Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002; 20: 13111318.
  • 19
    Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Flaherty LE, Smith T. Preliminary analysis of the E1690/S9111/C9190 intergroup postoperative adjuvant trial of high- and low-dose IFN-alfa 2b in high-risk primary or lymph node metastatic melanoma [abstract 2072]. Proc Am Soc Clin Oncol. 1999; 18: 537a.
  • 20
    Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998; 351: 19051910.
  • 21
    Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary Stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998; 16: 14251429.
  • 22
    Cameron DA, Cornbleet MC, MacKie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma—the Scottish Study. Br J Cancer. 2001; 84: 11461149.
  • 23
    Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001; 358: 866869.
  • 24
    Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004; 22: 5361.
  • 25
    Hauschild A, Weichenthal M, Balda B-R, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003; 21: 28832888.
  • 26
    Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003; 29: 241252.
  • 27
    Pirard D, Heenen M, Melot C, Vereecken P. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology. 2004; 208: 4348.
  • 28
    Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol. 1991; 9: 736740.
  • 29
    Spitler LE, Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med. 1980; 303: 11431147.
  • 30
    Loutfi A, Shakr A, Jerry M, Hanley J, Shibata HR. Double blind randomized prospective trial of levamisole/placebo in Stage I cutaneous malignant melanoma. Clin Invest Med. 1987; 10: 325328.
  • 31
    Lejeune FJ, Macher E, Kleeberg U, et al. An assessment of DTIC versus levamisole or placebo in the treatment of high risk Stage I patients after surgical removal of a primary melanoma of the skin. Eur J Cancer Clin Oncol. 1988; 24: S81S90.
  • 32
    Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with Stage III melanoma: the final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 1998; 187: 6977.
  • 33
    Livingston PO, Wong GY, Adluri S, et al. Improved survival in Stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994; 12: 10361044.
  • 34
    Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res. 2001; 7: 18821887.
  • 35
    Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol. 2002; 20: 41814190.
  • 36
    McIllmurray MB, Embleton MJ, Reeves WG, Langman MJ, Deane M. Controlled trial of active immunotherapy in management of Stage IIB malignant melanoma. BMJ. 1977; 1: 540542.
  • 37
    Aranha GV, McKhann CF, Grage TB, Gunnarsson A, Simmons RL. Adjuvant immunotherapy of malignant melanoma. Cancer. 1979; 43: 1297303.
  • 38
    Morton DL, Holmes FC, Eilber FR, Ramming KP. Adjuvant immunotherapy of malignant melanoma: results of a randomized trial in patients with lymph node metastases. In: TerryWD, RosenbergSA, editors. Immunotherapy of human cancer. New York: Excerpta Medica; 1982: 245249.
  • 39
    Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002; 20: 20582066.
  • 40
    Fisher RI, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am. 1981; 61: 12671277.
  • 41
    Sondak VK, Sosman J, Unger JM, et al. Significant impact of HLA Class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035 [abstract 7501]. Proc Am Soc Clin Oncol. 2004; 14S: 22.
  • 42
    Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982; 307: 913916.
  • 43
    Hansson J, Ringborg U, Lagerlof B, Strander H. Adjuvant chemotherapy of malignant melanoma. A pilot study. Am J Clin Oncol. 1985; 8: 4750.
  • 44
    Tranum BL, Dixon D, Quagliana J, et al. Lack of benefit of adjunctive chemotherapy in Stage I malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep. 1987; 71: 643644.
  • 45
    Hill GJ, Moss SE, Golomb FM, et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG Protocol 7040. Cancer. 1981; 47: 25562562.
  • 46
    Jacquillat C, Banzet P, Maral J. Clinical trials of chemotherapy and chemoimmunotherapy in primary malignant melanoma. Recent Results Cancer Res. 1982; 80: 254258.
  • 47
    Kerin MJ, Gillen P, Monson JR, Wilkie J, Keane FB, Tanner WA. Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for Stage I malignant melanoma. Eur J Surg Oncol. 1995; 21: 548550.
  • 48
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001; 19: 36353648.
  • 49
    Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol. 2001; 19: 36223634.
  • 50
    McMasters KM. The Sunbelt Melanoma Trial. Ann Surg Oncol. 2001; 8: 41S43S.
  • 51
    Quirt IC, DeBoer G, Kersey PA, Baker MA, Bodurtha AJ, Norvell ST. Randomized controlled trial of adjuvant chemotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. CMAJ. 1983; 128: 929933.
  • 52
    Karakousis CP, Emrich LJ. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG. J Surg Oncol. 1987; 36: 235238.
  • 53
    Karakousis C, Blumenson L. Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. Eur J Cancer. 1993; 29: 18311835.